Tirofiban HCL

t is a synthetic, non-peptide inhibitor acting at glycoprotein (GP) IIb/IIIb receptor in human platelets.

Indications

Acute coronary syndrome (given with heparin); patients undergoing percutaneous transluminal coronary angioplasty (PTCA) or atherectomy.

Dosage

Adults : Loading dose of 0.4mcg/kg/minute I.V. for 30 minutes, followed by continuous I.V. infusion of 0.1mcg/kg/minute for 48 to 108 hours in patients being managed medically. Continue infusion for 12 to 24 hours after PTCA or atherectomy

Contra-Indications

Hypersensitivity, Active internal bleeding or history of bleeding diathesis within past 30 days, Cerebrovascular accident, Intracranial hemorrhage, intracranial neoplasm, arteriovenous malformation, aneurysm, or thrombocytopenia after previous tirofiban use. History, symptoms, or findings that suggest aortic dissection, Severe hypertension, Acute pericarditis, Major surgery or severe trauma within past 30 days, Concurrent use of other parenteral GP IIb/IIIa inhibitors.

Special Precautions

Renal disease, elderly patinets, pregnant or breastfeeding patients, children younger than age 18 (safety not established).

Side Effects

pinal-epidural hematoma, intracranial hemorrhage, Vasovagal reaction, bradycardia, hemopericardium, coronary artery dissection, occult bleeding, retroperitoneal hemorrhage, pelvic pain, hematuria, bleeding, thrombocytopenia, leg pain, pulmonary hemorrhage, diaphoresis, allergic reactions.

Drug Interactions

Clopidogrel, dipyridamole, nonsteroidal anti-inflammatory drugs, oral anticoagulants. Omeprazole, Vitamin A.